Advertisement
U.S. markets open in 3 hours 41 minutes

MiMedx Group, Inc. (MDXG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.880.00 (0.00%)
At close: 04:00PM EDT
7.88 0.00 (0.00%)
After hours: 04:28PM EDT

MiMedx Group, Inc.

1775 West Oak Commons Court, NE
Marietta, GA 30062
United States
770 651 9100
https://www.mimedx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees895

Key Executives

NameTitlePayExercisedYear Born
Mr. William F. Hulse IVGeneral Counsel & Chief Administrative Officer677.36kN/A1974
Dr. Robert Benjamin Stein M.D., Ph.D.President of Regenerative Medicine & Biologics Innovation639.28kN/A1951
Mr. Joseph H. CapperCEO & DirectorN/AN/A1964
Mr. Douglas C. Rice CPAChief Financial OfficerN/AN/A1966
Mr. Scott M. TurnerSenior Vice President of Operations & Procurement493.98kN/A1966
Mr. Matthew M. NotarianniHead of Investor RelationsN/AN/AN/A
Mr. Mark P. GravesSenior VP & Chief Compliance OfficerN/AN/A1966
Hilary DixonVice President of Investor Relations & Corporate Strategic CommunicationsN/AN/AN/A
Ms. Kate SurdezChief Human Resources OfficerN/AN/AN/A
Dr. David H. Mason Jr.Chief Medical OfficerN/AN/A1947
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

Corporate Governance

MiMedx Group, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 4. The pillar scores are Audit: 8; Board: 2; Shareholder Rights: 5; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.